CDC Issues Alert to Address Shortage of RSV Treatment Nirsevimab
October 24th 2023Nirsevimab-alip (Beyfortus; Sanofi and AstraZeneca) is a monoclonal antibody approved to prevent against respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants under 8 months of age born during or entering their first RSV season.
Read More
FDA Approves Pentavalent Vaccine for Most Common Serogroups That Cause Meningococcal Disease
October 20th 2023Penbraya (Pfizer Inc) is the first and only approved pentavalent vaccine that confers protection against the most common meningococcal serogroups—A, B, C, W-135, and Y, in individuals 10 through 25 years of age.
Read More
FDA Approves Pembrolizumab Resectable Non–Small Cell Lung Cancer
October 17th 2023Pembrolizumab (Keytruda) gains its sixth approval in non–small cell lung cancer (NSCLC), with the latest indication in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a monotherapy for the post-surgical adjuvant treatment of patients with resectable NSCLC.
Read More